Research Paper Volume 16, Issue 6 pp 5676—5702
Identification and validation of a novel signature based on macrophage marker genes for predicting prognosis and drug response in kidney renal clear cell carcinoma by integrated analysis of single cell and bulk RNA sequencing
Figure 10. Drug sensitivity analysis. The comparisons in IC50 of AKT inhibitor (A), Axitinib (B), Gefitinib (C), Pazopanib (D), Crizotinib (E), and Cisplatin (F) between the two risk groups.